Panitumumab dye during pancreatic surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests whether a targeted antibody with a fluorescent dye can help surgeons see and remove pancreatic cancer during planned surgery. It’s an early-phase study, so the main goal is to see if the approach is safe and useful around the time of the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed (biopsy) or strongly suspected pancreatic adenocarcinoma (a specific pancreatic cancer type)
- You are scheduled for planned “curative intent” surgery (the goal is to remove the cancer)
- You’re expected to live more than 12 weeks and are well enough to do daily activities (performance status not too low)
- Blood test results are high enough: hemoglobin at least 9 and platelets at least 100,000
- Certain minerals and hormone levels are in a safe range: magnesium, potassium, and calcium above the lab’s lower limit, and TSH below 13
- You have no recent investigational drug (within 30 days) and no major recent heart or stroke event
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of radiation therapy for people with pancreatic cancer who are going to have chemotherapy and then surgery. The radiation is 'painted' to give more dose to the tumor and less to nearby healthy tissue.
This trial tests a special dye drug (panitumumab-IRDye800) that may help surgeons better see lung cancer areas while operating. If it works, it could improve how well cancer tissue is found and removed during planned lung surgery.
This early-stage trial tests whether an injected medicine with a glowing dye (panitumumab-IRDye800) can help doctors better see pediatric brain tumors during planned surgery. If it works, it may help surgeons remove more tumor tissue safely.
This trial tests whether a medicine with a fluorescent dye (panitumumab-IRDye800) helps doctors better see certain tumors during surgery. It may help safer, more complete tumor removal for people with glioblastoma or vestibular schwannoma.
This trial tests whether a special dye (SGM-101) can help surgeons see remaining cancer cells during surgery for pancreatic cancer that has been treated before surgery. It may lead to more complete removal of the tumor.
This Phase 2 study tests a targeted medicine (panitumumab-IRDye800) given around the time of surgery for head and neck squamous cell cancer. It aims to improve doctors’ ability to find and remove cancer tissue during planned surgery.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.